4-O-carboxymethylascochlorin: RN given refers to (1R-(1alpha(2E,4E),2beta,6beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6438999 |
| CHEMBL ID | 129991 |
| SCHEMBL ID | 12587079 |
| MeSH ID | M0128569 |
| Synonym |
|---|
| CHEMBL129991 |
| 4-o-carboxymethylascochlorin |
| 2-[2-chloro-4-formyl-5-hydroxy-3-methyl-6-[(2e,4e)-3-methyl-5-[(1r,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl]penta-2,4-dienyl]phenoxy]acetic acid |
| i1bk0ze06x , |
| 84435-25-6 |
| unii-i1bk0ze06x |
| acetic aicd, (2-chloro-4-formyl-5-hydroxy-3-methyl-6-(3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl)phenoxy)-, (1r-(1alpha(2e,4e),2beta,6beta))- |
| as-6 |
| acetic acid, (2-chloro-4-formyl-5-hydroxy-3-methyl-6-(3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl)phenoxy)-, (1r-(1.alpha.(2e,4e),2.beta.,6.beta.))- |
| acetic acid, (2-chloro-4-formyl-5-hydroxy-3-methyl-6-((2e,4e)-3-methyl-5-((1r,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl)phenoxy)- |
| acetic acid, 2-(2-chloro-4-formyl-5-hydroxy-3-methyl-6-((2e,4e)-3-methyl-5-((1r,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadien-1-yl)phenoxy)- |
| SCHEMBL12587079 |
| Q27280244 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Nuclear receptor subfamily 1 group I member 2 | Homo sapiens (human) | MEC | 30.0000 | 1.0000 | 1.6667 | 3.0000 | AID161437 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID156284 | Minimum effective concentration required to inhibit Peroxisome proliferator activated receptor alpha (PPAR alpha); Not detected | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID38996 | Minimum effective concentration required to inhibit androgen receptor (AR) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID44172 | Concentration required for inhibition of C3H10T1/2 progenitor cell growth | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID70032 | Minimum effective concentration required to inhibit Estrogen receptor 2 (ER beta); Not detected | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID157109 | Minimum effective concentration required to inhibit Peroxisome proliferator activated receptor gamma (PPAR gamma) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID161437 | Minimum effective concentration required to inhibit pregnane X receptor (PXR) | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| AID69869 | Minimum effective concentration required to inhibit Estrogen receptor 1 (ER alpha); Not detected | 2003 | Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19 | Ascochlorin derivatives as ligands for nuclear hormone receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||